COVID-19 Seroprevalence Study in French Guiana

Covid19 Clinical Trial

— EPI-COVID-POP  

Official title:

COVID-19 Seroprevalence Study in French Guiana

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04490850
• Other study ID #: 2020-048
• Status: Completed
• Phase: N/A
• Start date: July 15, 2020
• Est. completion date: September 24, 2021

Study information

• Verified date: February 2022
• Source: Institut Pasteur
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Description:

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

This study is a interventional study that present minimal risks and constraints.

The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3541
• Est. completion date: September 24, 2021
• Est. primary completion date: September 24, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;

• State of health compatible with a blood sample as defined in the protocol

Exclusion Criteria:

• Inability to consent

• Person under guardianship or curatorship

• Known pathology or a health problem contraindicated with the collect of blood sample.

Related Conditions & MeSH terms

• Communicable Diseases
• Coronavirus Infection
• Coronavirus Infections
• COVID-19
• Covid19
• Infections
• SARS-CoV Infection
• Severe Acute Respiratory Syndrome

Intervention

Procedure:
• Blood sample
Blood sample

Locations

Country	Name	City	State
French Guiana	Centre Hospitalier Andrée Rosemon	Cayenne
French Guiana	Laboratoire de biologie méicale, Institut Pasteur de la Guyane	Cayenne
French Guiana	Laboratoires Eurofins Guyane	Cayenne
French Guiana	Laboratoire de biologie médicale de Kourou	Kourou
French Guiana	Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni	Saint-Laurent du Maroni

Sponsors (7)

Lead Sponsor	Collaborator
Institut Pasteur	Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana, Eurofins, Institut Pasteur de la Guyane, Laboratoire de biologie médicale de Kourou, French Guiana, Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana, Laboratoire de biologie médicale, Institut Pasteur de la Guyane

Country where clinical trial is conducted

French Guiana, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure of the COVID-19 immunity of the population	The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies	1 year
Secondary	Evaluation of the level of asymptomatic and pauci-symptomatic infections	The proportion of asymptomatic and pauci-symptomatic infections will be measured in the population	1 year